Serum 25-Hydroxyvitamin D and Cancer Risk: A Systematic Review of Mendelian Randomization Studies
Lawler T, Warren Andersen S
Nutrients · 48 citas
Cómo se estudió
- Diseño
- Revisión sistemática (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Institutes of Health
- Gobierno
- Medical Research Council
- Gobierno
- National Cancer Institute
- Gobierno
- National Cancer Institute of the National Institutes of Health [NIH/NCI]
- Gobierno
- NCI NIH HHS
- Subvenciones
- National Cancer Institute (R00CA207848); Medical Research Council (MC_PC_17228); National Institutes of Health (R00 CA207848)
Según 5 financiadores declarados y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2023-01-13 · Nutrients · vol. 15 · número 2 · pág. 422
- Editorial
- Multidisciplinary Digital Publishing Institute
- Citado
- 59 citas · más que el 97% de estudios similares · 4.1× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 93 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Vitamin D Research Studies · Bone health and osteoporosis research · Folate and B Vitamins Research
- Palabras clave
- Mendelian randomization, Medicine, Internal medicine, Oncology, Cancer, Prostate cancer, Odds ratio, Breast cancer, Colorectal cancer, Gynecology, Biology
- MeSH
- humans, colorectal neoplasms, ovarian neoplasms, lung neoplasms, calcifediol, vitamin d, risk factors, polymorphism, single nucleotide, female, male, mendelian randomization analysis
2 autores
- Thomas P. Lawler🇺🇸University of Wisconsin–Madison; University of Wisconsin Carbone Cancer Center
- Shaneda Warren Andersen🇺🇸 · autor de correspondenciaUniversity of Wisconsin–Madison; University of Wisconsin Carbone Cancer Center
Resumen
El texto original del estudio, en el idioma en que se publicó.
Epidemiological studies suggest that higher serum 25-hydroxyvitamin D is associated with lower risk for several cancers, including breast, prostate, colorectal, and lung cancers. To mitigate confounding, genetic instrumental variables (IVs) have been used to estimate causal associations between 25-hydroxivtamin D and cancer risk via Mendelian randomization (MR). We provide a systematic review of 31 MR studies concerning 25-hydroxyvitamin D and cancer incidence and mortality identified from biomedical databases. MR analyses were conducted almost exclusively in European-ancestry populations and identified no statistically significant associations between higher genetically predicted 25-hydroxyvitamin D and lower risk for total cancer or colorectal, breast, prostate, lung, or pancreatic cancers. In recent studies including ≥80 genetic IVs for 25-hydroxyvitamin D, null associations were reported for total cancer (odds ratio [95% confidence interval] per 1-standard deviation increase: 0.98 [0.93-1.04]), breast (1.00 [0.98-1.02]), colorectal (0.97 [0.88-1.07]), prostate (0.99 [0.98-1.01]), and lung cancer (1.00 [0.93-1.03]). A protective association was observed for ovarian cancer in the Ovarian Cancer Association Consortium (0.78 [0.63-0.96] per 20 nmol/L increase, p-trend = 0.03), but not in the UK Biobank (1.10 [0.80-1.51]). Null associations were reported for other tumor sites (bladder, endometrium, uterus, esophagus, oral cavity and pharynx, kidney, liver, thyroid, or neural cells). An inconsistent protective association for cancer-specific mortality was also observed. Results from MR analyses do not support causal associations between 25-hydroxyvitamin D and risk for cancer incidence or mortality. Studies including non-White populations may be valuable to understand low 25-hydroxyvitamin D as a modifiable risk factor in populations with a higher risk of common cancers, including African ancestry individuals.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.